Allogeneic cell therapeutics are currently being developed to overcome manufacturing bottlenecks of autologous products but face allorejection as their biggest obstacle. This review analyzes the immunogenicity of allogeneic cell therapeutics, outlines engineering strategies for immune evasion, and summarizes recent milestone achievements.
